Skip to content

Hemoabsorption in Acute-On-Chronic Liver Failure

Hemoabsorption in Acute-On-Chronic Liver Failure - ALFA

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00033570
Enrollment
10
Registered
2024-03-11
Start date
2024-06-10
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K72

Interventions

Group 1: Absorbertherapy

Sponsors

Uniklinik RWTH Aachen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: ACLF with intensive care treatment and ongoing renal replacement therapy through an indwelling catheter, and indication for absorbertherapy

Exclusion criteria

Exclusion criteria: Pregnancy Acute Liver Failure

Design outcomes

Primary

MeasureTime frame
Hemodynamic stabilization, as indicated by reduction of vasopressor dosage and MAP (mean arterial pressure) in patients receiving absorption therapy.

Secondary

MeasureTime frame
- 30-day-and 60-day-mortality - Length of stay (LOS) on ICU - Indicators for stabilization of inflammatory conditions, such as white blood cell count, differential analyses of neutrophils and monocytes - Serum CRP, PCT, IL6, IL10 and TNFa - Serum bile acid concentrations - Serum bilirubin concentrations - Liver organ function, as indicated by INR and coagulation factor V

Countries

Germany

Contacts

Public ContactAlexander Koch

Uniklinik RWTH Aachen

mk3@ukaachen.de+49 241 80 80860

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026